Read more here
Welcome to OncoGeneX
News & Events
OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference
OncoGenex Announces Plans for the Initiation of the Cedar™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Squamous...
OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting
Exploring New Compounds to Meet the Challenge of Cancer Treatment Resistance
OncoGenex is a leader in the development of novel therapeutics that target important mechanisms of treatment resistance in cancer. We are committed to the development and commercialization of first-in-class, innovative therapies that have the potential to redefine treatment outcomes for patients with a variety of cancers.
Learn more about cancer treatment resistance.
Product Pipeline
Information:
For PatientsFor PhysiciansFor InvestorsOGX-427 is a once-weekly intravenous (IV) experimental drug designed to inhibit the production of heat shock protein 27 (Hsp27), a protein that is elevated in many cancers and that has been shown to promote cancer cell growth and tumor metastasis. By inhibiting Hsp27, OGX-427 may disable cancer cells’ defenses and overcome treatment resistance. Both the potential single-agent activity and synergistic activity of OGX-427 with cancer treatments may increase the overall benefit of existing therapies and augment the durability of treatment outcomes, which could lead to increased patient survival.




